Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis
- PMID: 33091374
- PMCID: PMC7572090
- DOI: 10.1016/S1473-3099(20)30769-6
Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis
Erratum in
-
Correction to Lancet Infect Dis 2020; published online Oct 19. https://doi.org/10.1016/S1473-3099(20)30769-6.Lancet Infect Dis. 2021 Jan;21(1):e1. doi: 10.1016/S1473-3099(20)30865-3. Epub 2020 Nov 6. Lancet Infect Dis. 2021. PMID: 33166489 Free PMC article. No abstract available.
Abstract
Background: As the COVID-19 pandemic continues to unfold, the infection-fatality risk (ie, risk of death among all infected individuals including those with asymptomatic and mild infections) is crucial for gauging the burden of death due to COVID-19 in the coming months or years. Here, we estimate the infection-fatality risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in New York City, NY, USA, the first epidemic centre in the USA, where the infection-fatality risk remains unclear.
Methods: In this model-based analysis, we developed a meta-population network model-inference system to estimate the underlying SARS-CoV-2 infection rate in New York City during the 2020 spring pandemic wave using available case, mortality, and mobility data. Based on these estimates, we further estimated the infection-fatality risk for all ages overall and for five age groups (<25, 25-44, 45-64, 65-74, and ≥75 years) separately, during the period March 1 to June 6, 2020 (ie, before the city began a phased reopening).
Findings: During the period March 1 to June 6, 2020, 205 639 people had a laboratory-confirmed infection with SARS-CoV-2 and 21 447 confirmed and probable COVID-19-related deaths occurred among residents of New York City. We estimated an overall infection-fatality risk of 1·39% (95% credible interval 1·04-1·77) in New York City. Our estimated infection-fatality risk for the two oldest age groups (65-74 and ≥75 years) was much higher than the younger age groups, with a cumulative estimated infection-fatality risk of 0·116% (0·0729-0·148) for those aged 25-44 years and 0·939% (0·729-1·19) for those aged 45-64 years versus 4·87% (3·37-6·89) for those aged 65-74 years and 14·2% (10·2-18·1) for those aged 75 years and older. In particular, weekly infection-fatality risk was estimated to be as high as 6·72% (5·52-8·01) for those aged 65-74 years and 19·1% (14·7-21·9) for those aged 75 years and older.
Interpretation: Our results are based on more complete ascertainment of COVID-19-related deaths in New York City than other places and thus probably reflect the true higher burden of death due to COVID-19 than that previously reported elsewhere. Given the high infection-fatality risk of SARS-CoV-2, governments must account for and closely monitor the infection rate and population health outcomes and enact prompt public health responses accordingly as the COVID-19 pandemic unfolds.
Funding: National Institute of Allergy and Infectious Diseases, National Science Foundation Rapid Response Research Program, and New York City Department of Health and Mental Hygiene.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Figures
Similar articles
-
SARS-CoV-2 infection and mortality during the first epidemic wave in Madurai, south India: a prospective, active surveillance study.Lancet Infect Dis. 2021 Dec;21(12):1665-1676. doi: 10.1016/S1473-3099(21)00393-5. Epub 2021 Aug 13. Lancet Infect Dis. 2021. PMID: 34399090 Free PMC article.
-
Preliminary Estimate of Excess Mortality During the COVID-19 Outbreak - New York City, March 11-May 2, 2020.MMWR Morb Mortal Wkly Rep. 2020 May 15;69(19):603-605. doi: 10.15585/mmwr.mm6919e5. MMWR Morb Mortal Wkly Rep. 2020. PMID: 32407306
-
Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study.BMJ. 2020 Nov 27;371:m4509. doi: 10.1136/bmj.m4509. BMJ. 2020. PMID: 33246972 Free PMC article.
-
Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics.Lancet Infect Dis. 2020 Sep;20(9):e238-e244. doi: 10.1016/S1473-3099(20)30484-9. Epub 2020 Jul 3. Lancet Infect Dis. 2020. PMID: 32628905 Free PMC article. Review.
-
A particle swarm optimization approach for predicting the number of COVID-19 deaths.Sci Rep. 2021 Aug 16;11(1):16587. doi: 10.1038/s41598-021-96057-5. Sci Rep. 2021. PMID: 34400735 Free PMC article. Review.
Cited by
-
Role of new vaccinators/pharmacists in life-course vaccination.Ann Med. 2024 Dec;56(1):2411603. doi: 10.1080/07853890.2024.2411603. Epub 2024 Oct 25. Ann Med. 2024. PMID: 39453787 Free PMC article. Review.
-
Spatial scales of COVID-19 transmission in Mexico.PNAS Nexus. 2024 Jul 31;3(9):pgae306. doi: 10.1093/pnasnexus/pgae306. eCollection 2024 Sep. PNAS Nexus. 2024. PMID: 39285936 Free PMC article.
-
Infectious disease surveillance needs for the United States: lessons from Covid-19.Front Public Health. 2024 Jul 15;12:1408193. doi: 10.3389/fpubh.2024.1408193. eCollection 2024. Front Public Health. 2024. PMID: 39076420 Free PMC article. Review.
-
Inference on spatiotemporal dynamics for coupled biological populations.J R Soc Interface. 2024 Jul;21(216):20240217. doi: 10.1098/rsif.2024.0217. Epub 2024 Jul 10. J R Soc Interface. 2024. PMID: 38981516 Free PMC article.
-
Syndecan-1 as a prognostic biomarker in COVID-19 patients: a retrospective study of a Japanese cohort.Thromb J. 2024 Jun 21;22(1):52. doi: 10.1186/s12959-024-00619-2. Thromb J. 2024. PMID: 38907229 Free PMC article.
References
-
- WHO . World Health Organization; Geneva: Oct 5, 2020. Coronavirus disease (COVID-2019) situation reports.https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situatio...
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous